In 2025, the Russian retail market for nebulizers (including marketplaces) amounted to RUB 4.6 billion (at retail prices, including VAT). Over the past year, Russians purchased 2.1 million units of various types of inhalers. Compared to 2024, sales volume in this category fell in both value (-7.4%) and physical terms (-5.4%). Notably, this decline in demand is the first recorded in several years, likely due to a relatively favorable situation with ARVI incidence last year, as well as a certain saturation of the market with these devices. In 2024, physical sales growth for inhalers exceeded 15.6%, and in 2023 the dynamics were +11.1% in units. At the same time, sales dynamics for drugs used for nebulizer inhalation in 2025 showed a growth rate of +19.9% in packages, while spending on these drugs increased by 6.9% over the year.

According to the database "Retail Audit of Drug Sales in Russia (total sell out)" from the analytical company RNC Pharma, among the analyzed drugs used in inhalers, the main volume in 2025 was accounted for by two brands: Pulmicort (INN budesonide) from AstraZeneca and Berodual (INN ipratropium bromide + fenoterol) from Boehringer Ingelheim. Together, these two brands accounted for 91% of the market in packages and 94% in value terms.

Demand for inhalers and the corresponding set of drugs typically increases during the seasonal respiratory disease period. In the past year, the peak in sales was observed in December 2025, when nearly 270,000 units of nebulizers worth RUB 629 million were sold at retail. Compared to the same month in 2024, spending on nebulizers increased by 28%, and physical consumption increased by 15%. The minimum sales volume (88,000 units worth RUB 192 million) in 2025 was recorded in July. Starting in August, an upward trend was observed, with the autumn peak occurring in October, when Russians purchased 208,000 devices worth RUB 444 million. At the beginning of this year (January–February 2026), a decline in nebulizer consumption was observed, particularly noticeable in February, when the total volume of purchased inhalers in Russia did not exceed 189,000 units worth RUB 404 million. The leader in the nebulizer category in terms of value volume at the end of the first two months of 2026 remains the Japanese corporation Omron with a 27% market share in rubles. In second place in the ranking is the Swiss company B.Well (23%), and rounding out the top three is the Japanese company A&D (18%).

Sales of nebulizers and inhalation solutions expectedly demonstrate synchronous seasonality. The demand dynamics in both segments are completely identical. For example, in December 2025, Russians purchased 2.3 million packages of such drugs worth RUB 1.2 billion, with long-term dynamics looking quite impressive — compared to December 2024, sales of inhalation products increased by 43% in packages, and spending increased by 46%.

Fig. Sales Volume of Nebulizers and Drugs for the Treatment of Obstructive Respiratory Diseases Used in Inhalers on the Russian Retail Market (including the online channel) for the Period from January 2025 to February 2026

*Drugs analyzed were from group R03 (antiasthmatic drugs and drugs for COPD treatment) in the form of solutions and suspensions based on beclomethasone, budesonide, ipratropium bromide and its combinations, salbutamol, and fenoterol.